Literature DB >> 21270142

Planning and core analyses for periodic aggregate safety data reviews.

H Amy Xia1, Brenda J Crowe, Robert C Schriver, Manfred Oster, David B Hall.   

Abstract

BACKGROUND: In 2009, the Safety Planning, Evaluation and Reporting Team gave detailed recommendations for a well-planned and systematic approach for safety data collection and analysis. Important aspects of this approach included regular reviews of aggregate data by a multidisciplinary team focusing on safety.
PURPOSE: This article provides information to facilitate the planning and implementation of aggregate data reviews.
METHODS: Our recommendations are based on experience of the authors and review of relevant literature.
RESULTS: We present information regarding the planning of aggregate data reviews as well as examples of data displays that are useful for many different compounds. A subset of these data displays could form a set of 'core' analyses to be generated for aggregate data reviews.

Mesh:

Year:  2011        PMID: 21270142     DOI: 10.1177/1740774510395635

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  4 in total

1.  A hierarchical testing approach for detecting safety signals in clinical trials.

Authors:  Xianming Tan; Bingshu E Chen; Jianping Sun; Tejendra Patel; Joseph G Ibrahim
Journal:  Stat Med       Date:  2020-02-12       Impact factor: 2.373

2.  Safety monitoring in clinical trials.

Authors:  Bin Yao; Li Zhu; Qi Jiang; H Amy Xia
Journal:  Pharmaceutics       Date:  2013-01-17       Impact factor: 6.321

3.  The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations.

Authors:  Janet Wittes; Brenda Crowe; Christy Chuang-Stein; Achim Guettner; David Hall; Qi Jiang; Daniel Odenheimer; H Amy Xia; Judith Kramer
Journal:  Stat Biopharm Res       Date:  2015-10-09       Impact factor: 1.452

4.  Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug Application.

Authors:  Patrick Archdeacon; Cheryl Grandinetti; José M Vega; David Balderson; Judith M Kramer
Journal:  Ther Innov Regul Sci       Date:  2014-03       Impact factor: 1.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.